129 Xenon Imaging in Patients Treated With Sotatercept

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Bastiaan Driehuys
Study ID
NCT06351345
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Pulmonary Arterial Hypertension
  • Pulmonary Hypertension

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • 129Xe Hyperpolarized — DRUG
    Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).

Study Details

Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).

Key Dates

Start date
Oct 27, 2025
Status verified
Feb 2026
Primary completion
Feb 4, 2029
Completion
Feb 4, 2030

Study Design

Enrollment
14 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Other: Pulmonary Arterial Hypertension Patients Receving Sotatercept
    PAH patients receiving sotatercept as treatment for their PAH

Primary Outcome Measure

Change in Xenon MRI Red Blood Cell (RBC) percentage [ Time Frame: baseline, 3,and 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Duke University Medical CenterDurhamNorth Carolina27710
Claudia Salazar, BS
[email protected]
919-660-2026
Sudarshan Rajagopal, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Durham, NC

By research site
Duke University Medical Center· Durham, NC

Related Studies